The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Practical reference · maintained document

Access notes: Ireland

Maintainers: PharmNotes_Whitfield, v.szabo, cohort_watch, crossref_check Last updated 31 May 2026 Next review due 22 June 2027 339 words · 5 revisions
Sourced from a discussion. This document was promoted out of NHS criteria and how they are applied in practice, in UK & Ireland. That topic links back here, and corrections raised there flow into this page.

Regulator, prescription status, reimbursement position and practical access route for Ireland. Every claim dated, because this changes constantly.

Scope and expiry

Practical access notes for Ireland: who regulates, what prescription status applies, how reimbursement is decided, and what route people actually use.

This page expires. Access conditions in this field have changed several times a year since 2023. The review date at the top of this page is the date it was last checked against primary sources. If you are making a decision, read the current official document rather than this page.

Regulatory and prescription position

The Health Products Regulatory Authority is the national regulator, operating within the EU framework. Licensed products in this class are prescription-only.

Coverage and cost

Reimbursement decisions run through national schemes and have historically been more restrictive for weight-management indications than for diabetes indications. That distinction is the single most useful thing to understand before an appointment.

The market is small, which means supply interruptions bite harder and substitution options are fewer than in larger member states.

The route people actually use

In practice the access question in Ireland resolves into three sub-questions: whether a prescription can be obtained, whether it will be funded, and whether the product is currently in supply. Those have different answers and different remedies, and conflating them is the commonest reason a member gets stuck.

If funding is the obstacle, the appeal discussion in Access is more useful than another consultation. If supply is the obstacle, the national shortage register — where one exists — is the only source worth reading.

What this page will not help with

This page does not describe how to obtain unlicensed material, and this community does not assist with that. It also does not tell you whether something is legal for you to possess, because that depends on facts about you that a documentation page cannot know.

Research-use-only material is not a licensed medicine in Ireland or anywhere else we are aware of.

Contributing

Regional pages are maintained by members in the region. If you can confirm or contradict anything here from a primary source, post in the regional category with the source and the date. An undated claim in this area is worse than no claim, and we will ask for the date.

Revision history

2026-05-31ms_hollowayRecorded a dissent from one maintainer rather than resolving it silently.
2026-04-26dietitian_hollisRestructured into shorter sections so the outline navigation is usable.
2026-02-08NLoughranAdded the worked example that the review thread asked for.
2025-10-26mira.patelAdded cross-references to the two topics that most often ask this question.
2025-06-01outline_firstInitial promotion from the source topic. Structure taken from the marked solution.

Every edit to a maintained document records its author and a note explaining the change. An edit without a note may be reverted by any wiki editor under R9, and the revert is logged. Disagreements about content belong on the source topic rather than in the revision history (R10).

Related documents

  • Access notes: United KingdomRegulator, prescription status, reimbursement position and practical access route for United Kingdom. Every claim…